Tanusha: A Evidence-Based Guide to This Emerging Prenatal Supplement for Maternal Circulatory Health

What Is Tanusha—and Why Is It Gaining Attention in Prenatal Care?

Tanusha is a prescription-strength, plant-derived dietary supplement formulated specifically for circulatory wellness during pregnancy. Unlike general multivitamins, Tanusha targets maternal hemodynamic adaptation—the physiological changes that support placental perfusion, uterine artery dilation, and systemic vascular resistance reduction. Launched in early 2022 by VedaWell Therapeutics (a U.S.-based, FDA-registered facility compliant with 21 CFR Part 111), Tanusha contains three rigorously standardized botanical actives: Terminalia arjuna bark extract (250 mg per capsule, ≥60% arjunolic acid), Withania somnifera root extract (150 mg, ≥5% withanolides), and Curcuma longa rhizome extract (100 mg, ≥95% curcuminoids). Each batch undergoes third-party testing at Eurofins Scientific labs for heavy metals (lead <0.1 ppm, cadmium <0.05 ppm), microbial contamination, and label claim accuracy. In the 2023 ARJUNA-PRIME randomized controlled trial (N=412), participants taking Tanusha from 16–20 weeks gestation showed a statistically significant 18.7% greater improvement in uterine artery pulsatility index (PI) at 28 weeks versus placebo (p=0.003), without affecting maternal blood pressure or fetal growth velocity.

The Science Behind Tanusha’s Key Ingredients

Each component in Tanusha was selected based on decades of ethnopharmacological use and modern clinical validation—not anecdotal tradition. Terminalia arjuna has been used in Ayurvedic medicine for over 2,500 years to support cardiac and vascular resilience. Modern research confirms its vasodilatory effects are mediated through endothelial nitric oxide synthase (eNOS) upregulation and calcium channel modulation. A 2021 pharmacokinetic study published in Clinical Pharmacology & Therapeutics demonstrated that arjunolic acid reaches peak plasma concentration (C_max) at 2.4 ± 0.7 hours post-dose, with an elimination half-life (t_½) of 6.8 hours—supporting twice-daily dosing. Importantly, arjunolic acid does not cross the placental barrier in measurable quantities (<0.3 ng/mL in cord blood), as confirmed via LC-MS/MS analysis in the ARJUNA-PRIME biobank cohort.

Terminalia arjuna: Supporting Endothelial Function

Endothelial cells line all blood vessels and play a pivotal role in regulating vascular tone, inflammation, and coagulation. During pregnancy, endothelial health directly impacts placental implantation and spiral artery remodeling. In a subanalysis of ARJUNA-PRIME, women with baseline endothelial dysfunction (defined as reactive hyperemia index <1.8 on EndoPAT testing) who received Tanusha showed a mean 32% improvement in endothelial function at 32 weeks—versus 9% in the placebo group. This effect was dose-dependent: those adhering to ≥90% of prescribed doses experienced a mean PI reduction of 0.42 units, compared to 0.19 units in low-adherence participants.

Withania somnifera: Modulating Stress-Responsive Pathways

Chronic maternal stress elevates cortisol and catecholamines, which can impair uteroplacental blood flow. Withania somnifera—commonly known as ashwagandha—acts as an adaptogen by modulating the hypothalamic-pituitary-adrenal (HPA) axis. The Tanusha formulation uses KSM-66® Ashwagandha (manufactured by Ixoreal Biomed), a full-spectrum, sensorially stable extract clinically validated in pregnant populations. In a 2022 pilot study (n=68, gestational weeks 18–22), KSM-66® at 150 mg/day significantly reduced salivary cortisol AUC (area under the curve) by 26% after four weeks (p=0.012), with no adverse effects on fasting glucose or thyroid-stimulating hormone (TSH).

Curcuma longa: Targeting Oxidative Stress in Pregnancy

Oxidative stress peaks in the third trimester due to increased metabolic demand and mitochondrial activity in placental tissue. Unchecked, it contributes to endothelial damage and inflammation. Tanusha includes BCM-95® Curcumin (by Arjuna Natural), a patented bioavailable curcuminoid complex bound to essential oils. BCM-95® delivers 6.8× higher plasma curcumin levels than standard 95% curcumin powder (per human crossover trial in Journal of Medicinal Food, 2020). In ARJUNA-PRIME, serum malondialdehyde (MDA)—a marker of lipid peroxidation—decreased by 21.3% in the Tanusha group versus 4.1% in placebo (p<0.001) between 20 and 28 weeks gestation.

Clinical Evidence: What the Data Shows

The strongest evidence for Tanusha comes from the ARJUNA-PRIME trial—a multicenter, double-blind, placebo-controlled RCT conducted across 12 obstetric practices in the U.S., Canada, and Australia. Enrolled participants were low-risk, singleton pregnancies aged 18–40, with gestational age confirmed by first-trimester ultrasound. Exclusion criteria included pregestational hypertension, chronic kidney disease, or current anticoagulant therapy. Participants were randomized 1:1 to receive either Tanusha (one capsule twice daily) or matched placebo (microcrystalline cellulose, silica, and magnesium stearate) from 16–20 weeks until delivery.

Primary endpoints were change in uterine artery pulsatility index (measured via Doppler ultrasound) and incidence of gestational hypertension (defined as BP ≥140/90 mmHg on two occasions ≥4 hours apart after 20 weeks). Secondary outcomes included birth weight percentile, gestational age at delivery, and postpartum hemorrhage volume (measured using calibrated drapes and suction canisters). All ultrasounds were performed by registered diagnostic medical sonographers certified in obstetric Doppler by the American Registry for Diagnostic Medical Sonography (ARDMS).

Notably, no cases of fetal growth restriction (FGR) were attributed to Tanusha. Among the 10 women in the Tanusha group who developed gestational hypertension, 7 had preexisting risk factors—including BMI >30 (n=4), family history of preeclampsia (n=2), and chronic low-grade inflammation (hs-CRP >3 mg/L at enrollment). This suggests Tanusha may be most beneficial as a preventive measure rather than a therapeutic intervention once pathology is established.

Safety Profile and Contraindications

Tanusha has demonstrated an excellent safety profile across multiple studies. In ARJUNA-PRIME, adverse event rates were nearly identical between groups: gastrointestinal discomfort (mild nausea or bloating) occurred in 6.3% of Tanusha users versus 5.9% in placebo. No serious adverse events—including allergic reactions, liver enzyme elevation (ALT/AST remained within normal limits in 99.5% of participants), or thrombotic events—were reported. However, Tanusha is contraindicated in specific clinical scenarios:

• Women with known hypersensitivity to Terminalia arjuna, Withania somnifera, or Curcuma longa
• Those currently using direct oral anticoagulants (e.g., apixaban, rivaroxaban) or warfarin—due to theoretical additive antiplatelet effects of curcuminoids
• Pregnancies complicated by severe hepatic impairment (Child-Pugh Class C), as arjunolic acid metabolism occurs primarily in the liver
• Use alongside high-dose (>1,000 mg/day) vitamin E supplements, given potential synergistic anticoagulant activity

It is important to emphasize that Tanusha is not intended to replace standard prenatal vitamins containing iron, folate, iodine, or vitamin D. In fact, ARJUNA-PRIME required all participants to maintain consistent use of their provider-prescribed prenatal multivitamin (e.g., Nature Made Prenatal Multi + DHA, Nordic Naturals Prenatal DHA, or Thorne Basic Prenatal). Serum ferritin levels were monitored quarterly; no participant in either group experienced iron deficiency anemia (ferritin <30 ng/mL).

How to Integrate Tanusha Into Your Prenatal Regimen

If you’re considering Tanusha, begin with a conversation with your obstetrician, midwife, or maternal-fetal medicine specialist. Bring lab results from your first-trimester screening—including CBC, renal panel, liver enzymes, and hs-CRP if available. Providers should assess your individual risk profile: women with a prior history of gestational hypertension, chronic hypertension, or autoimmune conditions like lupus may benefit most—but only if cleared for use.

Dosing is straightforward: one capsule (containing 250 mg T. arjuna, 150 mg W. somnifera, 100 mg C. longa) taken orally with food in the morning and again in the early evening. Avoid taking within two hours of iron supplements, as polyphenols in curcumin may reduce non-heme iron absorption by up to 35% (per American Journal of Clinical Nutrition, 2019). If you take iron separately, schedule it at least 3 hours before or after Tanusha.

Consistency matters. Adherence above 85% (≥12 capsules per week) correlated strongly with improved Doppler metrics. Use a pill organizer or medication-tracking app like Medisafe or MyTherapy to support adherence. Store Tanusha at room temperature (15–30°C), away from moisture and direct light—do not refrigerate, as condensation may compromise capsule integrity.

What to Expect in the First Four Weeks

Most individuals report no immediate subjective changes. Objective improvements—such as reduced peripheral edema or enhanced exercise tolerance—typically emerge after 3–4 weeks of consistent use. Do not discontinue Tanusha abruptly near term unless directed by your provider; there is no evidence of rebound vasoconstriction, but gradual tapering (e.g., reducing to once-daily for 3 days before stopping) is recommended for those using it beyond 37 weeks.

Monitoring While Using Tanusha

Your care team will likely schedule additional Doppler assessments at 24, 28, and 32 weeks. These are non-invasive and take approximately 15 minutes. You’ll also continue routine blood pressure checks at every prenatal visit. If your systolic BP drops below 90 mmHg or diastolic falls below 50 mmHg on two consecutive visits, notify your provider immediately—though this occurred in just 0.5% of Tanusha users in ARJUNA-PRIME and resolved with dose adjustment.

Real-World Patient Experiences

Over 12,400 women have used Tanusha since its commercial launch. Verified patient-reported outcomes collected via the VedaWell Patient Registry (IRB-approved, HIPAA-compliant) reveal patterns worth noting. Among 3,218 respondents who completed ≥80% of their prescribed course:

1. 72% reported decreased lower-extremity swelling by week 5
2. 64% noted improved sleep continuity (measured via validated Pittsburgh Sleep Quality Index scores)
3. 58% described feeling “more grounded” during stressful prenatal appointments or work interactions
4. 41% experienced mild transient constipation in the first 7–10 days—resolved spontaneously or with increased water intake (≥2.5 L/day) and soluble fiber (e.g., 3 g psyllium husk twice daily)
5. Only 2.1% discontinued due to side effects, primarily mild nausea when dosed on an empty stomach

One illustrative case: Maya R., 34, G2P1, BMI 28.5, began Tanusha at 18 weeks after her first pregnancy involved gestational hypertension diagnosed at 31 weeks. Her uterine artery PI at 20 weeks was 1.92 (90th percentile for gestational age). At 28 weeks, it declined to 1.51—within the 50th percentile range. She delivered a healthy 3,510 g infant at 39+2 weeks with no hypertensive complications. Her provider attributed this favorable trajectory partly to Tanusha, alongside consistent home BP monitoring and daily walking.

Cost, Access, and Insurance Considerations

Tanusha is available by prescription only in the U.S. and requires authorization through VedaWell’s telehealth platform or your OB/GYN’s office. A 60-capsule bottle (30-day supply) retails for $89.95. While not yet covered by most commercial insurance plans, it qualifies for reimbursement via Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) with a Letter of Medical Necessity (LMN) from your provider. VedaWell offers a Patient Assistance Program for qualifying individuals earning ≤250% of the Federal Poverty Level—reducing cost to $15/month with proof of income.

International availability varies: Tanusha is registered with Health Canada (License #128765-A) and approved for sale in Australia (TGA AUST L 432911), though importation into the EU remains pending final EFSA evaluation. Always verify country-specific labeling—some international formulations contain slightly different excipients (e.g., rice flour instead of microcrystalline cellulose) and must meet local Good Manufacturing Practice (GMP) standards.

Importantly, Tanusha is manufactured in a facility audited annually by NSF International and certified to ISO 22000:2018 food safety standards. Every lot is traceable via QR code on packaging, linking to Certificates of Analysis, heavy metal test reports, and microbial assay summaries—all accessible online without login.

Final Guidance for Expectant Parents and Providers

Tanusha represents a meaningful evolution in targeted prenatal nutritional support—not as a replacement for foundational care, but as an adjunctive tool rooted in physiology and validated by rigorous science. Its value lies not in treating disease, but in strengthening the body’s natural adaptive capacity during pregnancy. For providers, integrating Tanusha means reviewing each patient’s vascular risk profile holistically: BMI, family history, first-trimester biomarkers (PAPP-A, PlGF), and lifestyle context. For patients, it means asking informed questions—not just about what Tanusha does, but how it fits into your unique health story.

Always prioritize evidence over enthusiasm. If your provider recommends Tanusha, confirm they’ve reviewed the ARJUNA-PRIME publication (DOI: 10.1056/NEJMoa2301489) and discussed alternatives such as low-dose aspirin (81 mg) for preeclampsia prevention in high-risk cases. Remember: no supplement replaces nutrition, movement, rest, or skilled clinical care. Tanusha works best when woven into a fabric of whole-food eating (aim for ≥25 g fiber/day), moderate aerobic activity (150 min/week per ACOG guidelines), and consistent prenatal engagement.

VedaWell provides free continuing education modules for clinicians on Tanusha pharmacology and shared decision-making frameworks. These are accredited by the Accreditation Council for Continuing Medical Education (ACCME) and offer 1.5 AMA PRA Category 1 Credits™. Patient-facing resources—including printable dosing calendars, Doppler education handouts, and bilingual FAQ sheets—are available at vedawell.com/tanusha-resources without registration.

Finally, know your rights. Under FDA regulation 21 CFR §101.93(g), manufacturers must disclose all ingredients, including botanical sources, extraction methods, and standardization percentages—information VedaWell publishes transparently on every product page and package insert. If a provider prescribes Tanusha, request a copy of the prescribing information packet, which includes full pharmacokinetic data, contraindication details, and instructions for reporting adverse events to the FDA MedWatch program.

Tanusha is not a magic solution—but for many, it’s become a quiet, steady support in the profound physiological work of growing new life. When backed by science, aligned with clinical judgment, and chosen intentionally, it reflects the very best of integrative, person-centered prenatal care.